Thursday, July 7, 2011

Caterpillar Inc. Trading Above Price Target

On Thursday, July 7th, Caterpillar, Inc. continued a 3 week surge and eclipsed our price target of $108.74.  After discussion amongst the board, we have decided it is in our best interest to stay disciplined to group guidelines and sell the remainder of our position in CAT.  Since its inception to the portfolio in 2008, CAT has returned over 325% and paid a consistent dividend.  We see this as an excellent opportunity to reap our tremendous gains from Caterpillar and pursue other opportunities that present more upside at this time.

-Jeremy Pellizzari

Wednesday, July 6, 2011

Fiserv acquires CashEdge

Fiserv (FISV) has acquired CashEdge Inc. for $465 million in cash. "CashEdge provides an attractive suite of solutions to further enable the delivery of a highly differentiated payments experience for financial institutions and their customers, as well as accelerate the coming P2P movement," said Jeffery Yabuki, President and CEO.


This moves fits with Fiserv’s history of making smaller strategic acquisitions. Management believes the transaction will be neutral to 2011 EPS, and positive in 2012. It will be interesting to see how this move impacts the rate of share repurchases. The board authorized an additional 7.5 million shares in May, and UASBIG’s model assumes that total will be spread evenly over the next eight quarters. At this time there is not enough evidence to update the target price, which stands at $72.49 or 12% above today’s close of 64.75.

Zach

Thursday, June 30, 2011

JOYG closes at 95.24 +5.13(5.69%)

At the closing bell, JOYG climbed 5.13(5.69%) to 95.24. Despite poor US manufacturing results, industrial companies have seen excellent results in the last week and a half. Joy Global’s recent success can be attributed to their acquisition of Letourneau Technologies, which was finalized on June 22(blogged on May 16).

As reported in the release of JOYG’s 2-Q results, China’s stockpiles of coal touched a yearly low in April, which has created a shortage for the coming summer. Also, the effects of major earthquakes and droughts in Asia have created a reduction in the usage of Hydro generation and nuclear generators. This should bode well for coal demand and production. In the 1-Q of 2011, US coal exports rose 49% to its highest level of exports since 1992. The industry witnessed a 160% increase in steam coal demand, in the same period.

-Jim

CAT Bounces Back

Since June 15th, Caterpillar, Inc. has surged nearly 12% to $106.46, a price not seen since mid-May.  This latest run reflects the flash of confidence investors are showing and their willingness to seek riskier assets.  Although CAT released their plan to invest $120M into a factory and hire over 200 employees, it is believed that this run was not specifically related to any news from the company.  CAT is currently approaching their target price of $108.74 and will be closely monitored in the coming days.

Jeremy Pellizzari

Tuesday, June 28, 2011

Nike 4Q Review

Nike, Inc. reported 4Q results after the close on Monday and held an investor conference today. The company reported quarterly EPS of $1.24 versus street expectation of $1.16 and our modeled $1.09. 4Q2011 net revenues were $5.7bn, a 14% increase from last year and greater than the 9% analyst consensus. Gross margin, as expected, decreased 310 basis points due to increased inflation and sourcing costs. Full year revenue was $20.8 bn. 7.5mn shares were repurchased during the quarter for a total of $607mn.

Top-line performance was driven by 21% growth in the North American market, 16% in the Greater China region and 19% in Emerging Markets; partially offset by a 1% decline in Central/Eastern Europe and -26% in Japan. Inventory increased 33% on a year-over-year basis, which management commented was due to early summer shipments. Total futures orders, a key determinant of upcoming demand, were up 12% on a consolidated basis versus the expected 9%.

CEO Mark Parker commented during the investor presentation today that “Nike holds more than twice the number of invention patents than its closest top 5 competitors combined.” Last year, Parker stated that a company-wide goal was to report net revenues north of $27bn by FY2014. During today’s conference, he not only stated that they were well ahead of meeting that mark, but also revised the guidance up to $28 to $30bn.

Shares of the stock surged over 10% during the day. Notably, the higher than expected top-line growth was more than enough to offset the significant decline in gross margin. Additional pressure on gross margin continues to be the major risk going forward, as any major deceleration in sales would quickly flow through and affect the bottom-line. Nike is well positioned within the large emerging markets and retains several competitive advantages, solidifying its position as a growth story.

-Ian

Endo Pharmaceuticals (ENDP) Court Ruling

Endo Pharmaceuticals (ENDP) dropped 1.8% today after a U.S. federal court ruled unfavorably in a case regarding the pain-relief patch Lidoderm. The firm has been in litigation with Watson Pharmaceuticals (WPI) over Watson's potential patent infringement. Watson has been attempting to market a generic version of Lidoderm, a product which comprises approximately 30% of Endo Pharmaceutical's revenues. Although the actual patent-infringement trial will not begin until February 2012, the court sided with Watson's interpretation of the Lidoderm patent, causing shares of WPI to rise 4.2%, and shares of ENDP to fall 1.8%.

It is my view that the court ruling will not have a significant impact on ENDP. Although Lidoderm is an important part of Endo Pharmaceuticals drug portfolio, with 30% of net revenues, its importance to the firm has been diminishing over the past few years. At one point the drug represented 60% of revenues, but the proportion has been decreasing as the firm has continued to successfully diversify its product line-up. In addition, the court ruling does not absolve Watson Pharmaceuticals from the patent-infringement accusation. Whether or not ENDP will actually face generic competition will not be decided until February 2012. With Lidoderm's impact weakening, and Endo Pharmaceuticals strong prospects in the tamper-resistant Opana, the ruling should not pose a significant threat to the firm or our investment.

-Ryan M. Kennedy

Wednesday, June 15, 2011

Rambus Inc. v. Micron Technology Inc


Today the stock price of Micron Technology has dropped almost 4 % on the news that California judge will not impose bad shredding rulings on Rambus, Inc. Last month, the U.S. Court of Appeals for the Federal Circuit found Rambus was wrong to shred hundreds of boxes of documents relevant in two patent infringement lawsuits it filed. However, this time,  jurors will not be told by the court that Micron have already proven that the chipmaker shredded documents as part of its legal strategy, Instead, Hynix and Micron will have to present evidence on that issue. Rambus is suing Micron and Hynix for $4.3 billion and according to California laws, this amount might be tripled. 
In the light of these events we will be closely monitoring Micron, as the trial progresses.
-Vlad